TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23756392

Group type: EXPERIMENTAL
Intervention: Tianeptine 12.5 mg three times daily for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 100
Study: 21252141

Group type: EXPERIMENTAL
Intervention: efavirenz-based ART (600 mg)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: nevirapine-based ART (400 mg)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both efavirenz and nevirapine-based ART
Number of subjects: 168
Study: 18278626

Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention including 40 min of academic enrichment and 80 min of moderate-to-vigorous physical activity (MVPA)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study: 16920865

Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) (12.5 mg Fe + 50 mug folic acid)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) with or without Zinc (Zn) (10 mg)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Iron+folic acid (FeFA) alone
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) alone
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 12712025

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg, maximum dose 10 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 11061879

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide
Number of subjects: 21

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 21
Study: 9255435

Group type: EXPERIMENTAL
Intervention: RheothRx Injection (0.5 mg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RheothRx Injection (1 mg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RheothRx Injection (2 mg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RheothRx Injection (5 mg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RheothRx Injection (during CORE Trial)
Number of subjects: 46
Study: 8345429

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus platelet concentrates (10 ml/kg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 152
Study: 2942168

Group type: EXPERIMENTAL
Intervention: Orally-administered nickel (5.6 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lower doses of nickel
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30580652

Group type: EXPERIMENTAL
Intervention: Curcumin (CUR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dual Stress Challenge (DSC)
Number of subjects: 14
Study: 30052598

Group type: EXPERIMENTAL
Intervention: Mixed session periodization (MSP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional periodization (TP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 26835724

Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound system
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-end ultrasound system
Number of subjects: 40
Study: 25052387

Group type: EXPERIMENTAL
Intervention: Telehealth group (TG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Telehealth group (TG) for patients without comorbidity
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG) for patients without comorbidity
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Telehealth group (TG) for patients with comorbidity
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG) for patients with comorbidity
Number of subjects: 45
Study: 22782791

Group type: EXPERIMENTAL
Intervention: Duet (precoital use)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Duet (daily use)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both use-regimens
Number of subjects: 80

Group type: COMPARATOR
Intervention: Duet and BufferGel (overall adherence)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diaphragm experience
Number of subjects: 80
Study: 20593911

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Number of subjects: 846

Group type: COMPARATOR
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Up-titration from olmesartan medoxomil 40 mg to olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Up-titration from olmesartan medoxomil 40 mg/HCTZ 12.5 mg to olmesartan medoxomil 40 mg/HCTZ 25 mg
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Addition of HCTZ 12.5 mg to olmesartan medoxomil 40 mg
Number of subjects: 846

Group type: COMPARATOR
Intervention: Continuation on olmesartan medoxomil 40 mg
Number of subjects: 846
Study: 18370581

Group type: EXPERIMENTAL
Intervention: CTS-targeted massage (TM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: General massage (GM)
Number of subjects: 27
Study: 15747127

Group type: EXPERIMENTAL
Intervention: Vertical suture line related to midline (VLRM, n=16)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vertical suture line unrelated to midline (VLUM, n=18)
Number of subjects: 34
Study: 12209710

Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Postoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1234
Study: 10331708

Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine)
Number of subjects: 227
Study: 8923830

Group type: EXPERIMENTAL
Intervention: rhIGF‐I 100 micrograms/kg BID
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: rhIGF‐I 30 micrograms/kg BID
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1615140

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0
Study: 6087368

Group type: EXPERIMENTAL
Intervention: Pivmecillinam/pivampicillin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 139
Study: 30672832

Group type: EXPERIMENTAL
Intervention: ivabradine (Iva, 7.5 mg b.i.d.)
Number of subjects: 23
Study: 30592726

Group type: EXPERIMENTAL
Intervention: Diaphragm function parameters (thickness and range of motion)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Limitation of diaphragm motion during quiet breathing and deep breathing
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Diaphragm muscle excursion during sniff maneuvers
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Deterioration of diaphragm function after thoracic surgery
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Decrease of muscle thickness and movement restriction
Number of subjects: 142
Study: 28683244

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 0
Study: 24472122

Group type: EXPERIMENTAL
Intervention: High Five for Kids intervention
Number of subjects: 445

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study: 22253222

Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 20167185

Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Therapy (TBT) sessions conducted thrice weekly for 12 weeks by phone, lasting an average of 15 minutes each.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Therapy (TBT) sessions.
Number of subjects: 32
Study: 18055037

Group type: EXPERIMENTAL
Intervention: Combination fibrinolysis with 50 mg alteplase and tirofiban
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Upstream tirofiban
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (provisional abciximab)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combination fibrinolysis
Number of subjects: 151
Study: 16368450

Group type: EXPERIMENTAL
Intervention: T40/H12.5
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: T80/H12.5
Number of subjects: 1402

Group type: COMPARATOR
Intervention: L50/H12.5
Number of subjects: 1402
Study: 12449447

Group type: EXPERIMENTAL
Intervention: Healthy full-term infants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Healthy preterm infants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diseased preterm infants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study: 10323626

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8597321

Group type: EXPERIMENTAL
Intervention: Fluconazole, 200 mg/d for 2 weeks; then fluconazole, 200 mg/d and rifabutin, 300 mg/d for 2 weeks; then rifabutin, 300 mg/d for 2 weeks
Number of subjects: 12
Study: 1912915

Group type: EXPERIMENTAL
Intervention: Physical training (three extra lessons a week of an ordinary school physical education programme for eight months)
Number of subjects: 137
Study: 7231652

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 30141966

Group type: EXPERIMENTAL
Intervention: Cleaner-burning biomass-fueled cookstove intervention (CAPS)
Number of subjects: 1481
Study: 27712932

Group type: EXPERIMENTAL
Intervention: Lidocaine and clonidine (15 μg/ml)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lidocaine and adrenaline (12.5 μg/ml)
Number of subjects: 200
Study: 26206217

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) promotion and encouragement from health care professionals, including physical therapists, individually or in groups.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Individualized strategies to overcome challenges and barriers to PA.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Personal preferences and osteoporosis-related concerns influencing habitual PA.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lack of PA promotion and conflicting advice from physicians.
Number of subjects: 18
Study: 25812386

Group type: EXPERIMENTAL
Intervention: Jet engine noise exposure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-noise exposed)
Number of subjects: 60
Study: 21953475

Group type: EXPERIMENTAL
Intervention: Minimal Trauma Fracture Liaison (MTFL) service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 20305868

Group type: EXPERIMENTAL
Intervention: Cavit (3M ESPE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DuoTemp (Coltane/Whaledent)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketac (3M ESPE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination technique using Ketac and Cavit
Number of subjects: 100

Group type: COMPARATOR
Intervention: All materials (Cavit, DuoTemp, Ketac)
Number of subjects: 100
Study: 17608134

Group type: EXPERIMENTAL
Intervention: Hydroxy methyl propyl cellulose based formulation
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Poloxamer based formulation
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 441
Study: 15703343

Group type: EXPERIMENTAL
Intervention: Psychiatric services (average of at least 2.1 hours a year)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Less than 2.1 hours a year of psychiatric services
Number of subjects: 604
Study: 12193818

Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nyhus procedure
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bassini procedure
Number of subjects: 84

Group type: COMPARATOR
Intervention: TEP mesh hernioplasty
Number of subjects: 84
Study: 9790154

Group type: EXPERIMENTAL
Intervention: Continuation treatment (CT) with clonazepam for another 5 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuation treatment (DT) using a clonazepam taper at the rate of 0.25 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation treatment (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discontinuation treatment (DT)
Number of subjects: 0
Study: 7815837

Group type: EXPERIMENTAL
Intervention: Remission induction with 3 days daunorubicin and 7 days cytosine arabinoside
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Salvage treatment after initial induction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Consolidation treatment (standard maintenance, intensive consolidation courses, autologous or allogeneic transplantation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disease-free survival for patients less than 45 years of age with M2 and M3 subtypes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Projected survival for M3 patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Death rate during remission induction
Number of subjects: 80
Study: 2577568

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y + pouch
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interposition + pouch
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 78
Study: 29566443

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (MC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 28351410

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Rehabilitation (12 weekly group sessions of 90 min each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Rehabilitation
Number of subjects: 0
Study: 26708885

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (dendritic cells and cytokine‐induced killer cells, DC‐CIK) combined with chemotherapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (DC‐CIK) combined with chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 36
Study: 24083402

Group type: EXPERIMENTAL
Intervention: Deferasirox for up to 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21911192

Group type: EXPERIMENTAL
Intervention: Haloperidol and tropisetron (Group HT)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate and dexamethasone (Group DD)
Number of subjects: 480

Group type: COMPARATOR
Intervention: No prophylaxis (Group P)
Number of subjects: 480
Study: 18413496

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in HDL cholesterol
Number of subjects: 0
Study: 16789988

Group type: EXPERIMENTAL
Intervention: Cefepime 2G 12 hourly
Number of subjects: 255

Group type: COMPARATOR
Intervention: Ampicillin/Sulbactam 3 g 8 hourly and Aztreonam 2 g 8 hourly
Number of subjects: 255
Study: 12832310

Group type: EXPERIMENTAL
Intervention: Intensive Therapy (IT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142
Study: 11069815

Group type: EXPERIMENTAL
Intervention: TB‐FV loop analysis
Number of subjects: 113
Study: 8842575

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lactate + Acetazolamide infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetazolamide alone
Number of subjects: 0
Study: 1616890

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU), 13.5 mg/kg for five days (arm A)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (FA), 200 mg/m2 for five days and 5FU, 400 mg/m2 for five days (arm B)
Number of subjects: 181

Group type: COMPARATOR
Intervention: 5FU alone (arm A)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 5FU plus FA (arm B)
Number of subjects: 181
Study: 6387968

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (10 micrograms administered intravenously 5 minutes before amniocentesis)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30682037

Group type: EXPERIMENTAL
Intervention: Dengue vaccine with a true VE of 0.8
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Dengue vaccine
Number of subjects: 1000
Study: 29533864

Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin administration within the first minute following the delivery of the fetus (10 IU)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Intramuscular oxytocin administration immediately following placental delivery (10 IU)
Number of subjects: 343
Study: 26751193

Group type: EXPERIMENTAL
Intervention: Calcium plus hesperidin (500 g hesperidin with 500 mg calcium)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hesperidin alone
Number of subjects: 12
Study: 25248449

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation for 5 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 10
Study: 22775152

Group type: EXPERIMENTAL
Intervention: Tropicamide 1% vaporized in closed eyes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tropicamide 1% instilled in open eyes
Number of subjects: 50
Study: 20098310

Group type: EXPERIMENTAL
Intervention: Aqualase
Number of subjects: 75

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 75
Study: 17963493

Group type: EXPERIMENTAL
Intervention: Short Psychodynamic Supportive Psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy
Number of subjects: 0
Study: 15831773

Group type: EXPERIMENTAL
Intervention: Fenofibrate (201 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12472326

Group type: EXPERIMENTAL
Intervention: Clinical practice improvement intervention
Number of subjects: 7920

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 7920
Study: 9473999

Group type: EXPERIMENTAL
Intervention: Portable ultrasound device (PUD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 8998248

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 to 10 mg once daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 to 25 mg once daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combination therapy (HCTZ + AML) after 8 weeks of monotherapy
Number of subjects: 42
Study: 2115215

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 72
Study: 363217

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative metronidazole medication
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoperative mechanical bowel preparation and oral neomycin
Number of subjects: 30
Study: 29600588

Group type: EXPERIMENTAL
Intervention: 6-month programmed sports therapy (PST)
Number of subjects: 50
Study: 28241776

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 98
Study: 25958079

Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 441

Group type: COMPARATOR
Intervention: Active Control (Sevelamer Carbonate and/or Calcium Acetate)
Number of subjects: 441
Study: 23650950

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg HR, Thioctacid, three doses
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 21178591

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Number of subjects: 171
Study: 18808278

Group type: EXPERIMENTAL
Intervention: Craving condition (participants abstained from eating chocolate for 24 hours prior to testing and performed cognitive tasks in the presence of chocolate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (participants not specified, but presumably did not abstain from chocolate)
Number of subjects: 0
Study: 16302600

Group type: EXPERIMENTAL
Intervention: Orthodontic appliances (experimental group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no orthodontic appliances)
Number of subjects: 64
Study: 12077006

Group type: EXPERIMENTAL
Intervention: Visually guided saccades in Parkinson's disease subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Memory-guided saccades in Parkinson's disease subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Centripetal adaptation in Parkinson's disease subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Centrifugal adaptation in Parkinson's disease subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visually guided saccades in controls
Number of subjects: 24

Group type: COMPARATOR
Intervention: Memory-guided saccades in controls
Number of subjects: 24
Study: 9445301

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human IL-5
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle or 0.4 ng of endotoxin (Control)
Number of subjects: 8
Study: 7822813

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) infusion (133 mg/h)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endotoxin (20 U/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IL-1ra infusion with endotoxin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control study day (no treatment)
Number of subjects: 18
Study: 2214478

Group type: EXPERIMENTAL
Intervention: Intravesical BCG (80 mg Tokyo strain) administered at one week intervals for 6 weeks, two week intervals for 12 weeks, and one month intervals for 20 months.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no further treatment after TUR).
Number of subjects: 44